Tucatinib (ONT-380) progressing in pivotal trial against HER
Phase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The 50 women treated had progressed despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, with at least "stable disease" at 24 or more weeks after the start of treatment. These data led to two subsequent Phase Ib studies, resulting in tucatinib earning FDA fast-track status and the expansion of this study once meant only to demonstrate drug safety into the "pivotal" trial that will determine approval.

Read more at: http://medicalxpress.com/news/2017-01-tucatinib-ont-pivotal-trial-her2.html#jCp
Like
Comment
Share